Early Risk Stratification of Dosing Errors in Clinical Trials Using Machine Learning
Fuente:
arXiv
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Preprint |
| Publicado: |
2026
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866910033497817088 |
|---|---|
| author | Hêche, Félicien Ferdowsi, Sohrab Yazdani, Anthony Sansaloni-Pastor, Sara Teodoro, Douglas |
| author_facet | Hêche, Félicien Ferdowsi, Sohrab Yazdani, Anthony Sansaloni-Pastor, Sara Teodoro, Douglas |
| contents | Objective: The objective of this study is to develop a machine learning (ML)-based framework for early risk stratification of clinical trials (CTs) according to their likelihood of exhibiting a high rate of dosing errors, using information available prior to trial initiation. Materials and Methods: We constructed a dataset from ClinicalTrials.gov comprising 42,112 CTs. Structured, semi-structured trial data, and unstructured protocol-related free-text data were extracted. CTs were assigned binary labels indicating elevated dosing error rate, derived from adverse event reports, MedDRA terminology, and Wilson confidence intervals. We evaluated an XGBoost model trained on structured features, a ClinicalModernBERT model using textual data, and a simple late-fusion model combining both modalities. Post-hoc probability calibration was applied to enable interpretable, trial-level risk stratification. Results: The late-fusion model achieved the highest AUC-ROC (0.862). Beyond discrimination, calibrated outputs enabled robust stratification of CTs into predefined risk categories. The proportion of trials labeled as having an excessively high dosing error rate increased monotonically across higher predicted risk groups and aligned with the corresponding predicted probability ranges. Discussion: These findings indicate that dosing error risk can be anticipated at the trial level using pre-initiation information. Probability calibration was essential for translating model outputs into reliable and interpretable risk categories, while simple multimodal integration yielded performance gains without requiring complex architectures. Conclusion: This study introduces a reproducible and scalable ML framework for early, trial-level risk stratification of CTs at risk of high dosing error rates, supporting proactive, risk-based quality management in clinical research. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2602_22285 |
| institution | arXiv |
| publishDate | 2026 |
| record_format | arxiv |
| spellingShingle | Early Risk Stratification of Dosing Errors in Clinical Trials Using Machine Learning Hêche, Félicien Ferdowsi, Sohrab Yazdani, Anthony Sansaloni-Pastor, Sara Teodoro, Douglas Machine Learning Artificial Intelligence Objective: The objective of this study is to develop a machine learning (ML)-based framework for early risk stratification of clinical trials (CTs) according to their likelihood of exhibiting a high rate of dosing errors, using information available prior to trial initiation. Materials and Methods: We constructed a dataset from ClinicalTrials.gov comprising 42,112 CTs. Structured, semi-structured trial data, and unstructured protocol-related free-text data were extracted. CTs were assigned binary labels indicating elevated dosing error rate, derived from adverse event reports, MedDRA terminology, and Wilson confidence intervals. We evaluated an XGBoost model trained on structured features, a ClinicalModernBERT model using textual data, and a simple late-fusion model combining both modalities. Post-hoc probability calibration was applied to enable interpretable, trial-level risk stratification. Results: The late-fusion model achieved the highest AUC-ROC (0.862). Beyond discrimination, calibrated outputs enabled robust stratification of CTs into predefined risk categories. The proportion of trials labeled as having an excessively high dosing error rate increased monotonically across higher predicted risk groups and aligned with the corresponding predicted probability ranges. Discussion: These findings indicate that dosing error risk can be anticipated at the trial level using pre-initiation information. Probability calibration was essential for translating model outputs into reliable and interpretable risk categories, while simple multimodal integration yielded performance gains without requiring complex architectures. Conclusion: This study introduces a reproducible and scalable ML framework for early, trial-level risk stratification of CTs at risk of high dosing error rates, supporting proactive, risk-based quality management in clinical research. |
| title | Early Risk Stratification of Dosing Errors in Clinical Trials Using Machine Learning |
| topic | Machine Learning Artificial Intelligence |
| url | https://arxiv.org/abs/2602.22285 |